Dale Biotech, LLC

Dale Biotech, LLC, based in Kennedale, TX, is a cutting-edge biotechnology company focused on developing innovative solutions for diseases associated with adipose and endothelial inflammation. Their small molecule DBI-500 targets epicardial adipose inflammation linked to atrial fibrillation and cardiovascular risk, offering promising potential for the treatment of various conditions including Type 2 Diabetes, Obesity, and NASH.

Under the leadership of CEO Ralph Salvagno, MD, Dale Biotech is dedicated to leveraging their expertise in Rhamnolipids to address the global health crisis posed by COVID-19. Their unique oral formulation, incorporating niclosamide, shows early promise in treating and preventing COVID-19, demonstrating a commitment to advancing scientific solutions for current and future viral threats.

Generated from the website